knowledge -WSS

knowledge

author：explore 2025-09-29 22:50:03 - browse：2

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： AstraZeneca stays mum on Medicare drug pricing negotiations

WSS

Mystery swirls around US soldier who entered North Korea days ago, officials say

Are infertility treatments 'essential' during the Covid

Texas Medical Board asked to define abortion emergency exception

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Gene therapy for Afghan refugees’ infant will be fully covered

focus

knowledge

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Bernie brings in new pharma CEOs to talk drug prices

Hollywood unions extend contract negotiations for actors

Why CTE doesn’t keep Americans from enjoying the Super Bowl

George Santos makes 1st court appearance after pleading not guilty to 13 counts

After a decade, new Gardasil ad campaign gets it (mostly) right

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The stock market has soared this year, but will it last? Experts weigh in

Malaria cases in Florida and Texas: Here’s what you need to know

After a decade, new Gardasil ad campaign gets it (mostly) right

focus

Mystery swirls around US soldier who entered North Korea days ago, officials say

'CMA Fest' 2023: How to watch, who is performing and more

When a patient nears the end, a feared therapy can comfort

Sanders wants to replace patents with prizes for drug inventions

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Cano Health’s bankruptcy is a warning for Medicare Advantage

explore

focus

focus

entertainment